Use of enoxaparin in dogs with primary immune-mediated hemolytic anemia: 21 cases

Journal of Veterinary Emergency and Critical Care
Cynthia M PanekDomenico Bianco

Abstract

To describe the complications and frequency of thrombosis associated with the use of enoxaparin, a low molecular weight heparin, in dogs with primary immune-mediated hemolytic anemia (IMHA). Retrospective case series. Two privately owned veterinary referral hospitals. Twenty-one client-owned dogs with primary IMHA. Dogs were treated with enoxaparin (0.8 mg/kg subcutaneously every 6 h) as the sole anticoagulation therapy starting at admission to the hospital. Only 2 dogs had minor hemorrhagic complications associated with enoxaparin therapy. Frequency of thrombosis was not assessed. Long-term survival was comparable to other anticoagulation protocols reported for dogs with primary IMHA. The use of enoxaparin was safe in a small group of dogs with primary IMHA. Whether enoxaparin therapy can reduce mortality and thrombotic complications in dogs with primary IMHA compared with other anticoagulation protocols remains unknown.

References

Jan 1, 1993·Veterinary Pathology·T J Van Winkle, E Bruce
Jun 20, 1998·Arteriosclerosis, Thrombosis, and Vascular Biology·R J LeadleyM H Perrone
Aug 17, 1999·Journal of Veterinary Internal Medicine·L R JohnsonD C Baker
Sep 24, 1999·Journal of the American Animal Hospital Association·M E ReimerL D Warnick
Mar 7, 2001·Journal of the American Veterinary Medical Association·S A Grundy, C Barton
May 2, 2001·Journal of the American Veterinary Medical Association·P M McManus, L E Craig
May 22, 2001·Journal of the American Animal Hospital Association·J C Scott-MoncrieffM B Brooks
Jan 29, 2002·European Heart Journal·E M AntmanUNKNOWN TIMI 11B and ESSENCE Investigators
Aug 4, 2004·Circulation·Alain LeizoroviczUNKNOWN PREVENT Medical Thromboprophylaxis Study Group
Jun 7, 2005·Journal of the American Veterinary Medical Association·Tristan K WeinkleHollis N Erb
Jun 1, 2006·Journal of Veterinary Internal Medicine·Douglas J Weiss, Jennifer L Brazzell
Mar 19, 2008·Journal of Veterinary Internal Medicine·C J PiekE Teske
May 5, 2009·Journal of the American Animal Hospital Association·Elizabeth L BreuhlJ Catharine Scott-Moncrieff
Oct 14, 2009·Journal of Veterinary Emergency and Critical Care·Virginia B Sinnott, Cynthia M Otto
Nov 6, 2009·Journal of the American Animal Hospital Association·Kari V LunsfordMarjory Brooks
Apr 14, 2010·Journal of Veterinary Internal Medicine·S E HelmondS A Smith
Jun 30, 2010·International Journal of Technology Assessment in Health Care·Edmundas KaduseviciusDanguole Jankauskiene
Jul 14, 2010·The Journal of Small Animal Practice·A E RidyardE M Milne
Sep 16, 2010·Journal of Veterinary Internal Medicine·M P LaurensonE G Johnson
Dec 16, 2010·Journal of Veterinary Internal Medicine·A M MellettD Bianco
Feb 16, 2011·Journal of the American Veterinary Medical Association·Renee K FentyTherese E O'Toole
Apr 8, 2011·Expert Opinion on Pharmacotherapy·Zafar Iqbal, Marc Cohen

❮ Previous
Next ❯

Citations

Jan 18, 2019·Journal of Veterinary Emergency and Critical Care·Robert GoggsRonald H L Li
Jan 18, 2019·Journal of Veterinary Emergency and Critical Care·Marie-Claude BlaisClaire R Sharp
Jan 18, 2019·Journal of Veterinary Emergency and Critical Care·Armelle deLaforcadeElizabeth Rozanski
Mar 9, 2019·Journal of Veterinary Internal Medicine·James W SwannNathaniel T Whitley
Jul 14, 2020·The Journal of Veterinary Medical Science·Mona UchidaHajime Tsujimoto
Aug 21, 2020·The Veterinary Clinics of North America. Small Animal Practice·Robert Goggs
Oct 9, 2021·Journal of Veterinary Pharmacology and Therapeutics·Julianna FrumJohn Thomason

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Hemolytic Anemia

Autoimmune hemolytic anemia (AIHA) occurs when antibodies directed against the person's own red blood cells (RBCs) cause them to burst (lyse), leading to an insufficient number of oxygen-carrying red blood cells in the circulation. Discover the latest research on AIHA here.